西班牙Certest賈第鞭毛蟲抗體（克隆G22）

廣州健侖生物科技有限公司

廣州健侖長期供應各種生物原料，主要代理品牌：西班牙Certest。

主要產品包括各種生物單克隆抗原抗體、重組蛋白。

西班牙Certest賈第鞭毛蟲抗體（克隆G22）

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

【產品介紹】

西班牙

CN-CS1是*進入臨床試驗的*種療法，其是一種可以募集NKG2D細胞受體的自體CAR t細胞療法，NKG2D作為一種自然殺傷的細胞受體，其可以靶向作用大部分腫瘤中存在的配體，包括血液癌癥和實體瘤;研究者當前的臨床試驗時在血液癌癥中進行的，比如白血病和骨髓瘤等，當前臨床試驗療法的廣泛應用價值使其在癌癥研究領域具有較為深遠的前景。
同新一代的平臺技術一樣，許多相關的其它療法目前正在經歷臨床前的開發階段，來自Sentman實驗室開發的新一代平臺技術可以將CAR T細胞同另一種創新性的TCR-抑制分子(TIMs)相結合;TIMs可以使CAR療法被用于進行健康供體的T細胞研究中，從而可以避免后移植物的抗宿主反應(Graft-Versus-Host-Disease，GVHD)。一旦成功，TIM/CAR療法將會盡可能減少療法所用的時間，并且明顯降低患者開支。
zui后研究者Sentman說道，我們很高興可以有機會將我們開發的新型療法應用于臨床治療過程中，其對于開發新型得癌癥免疫療法具有非常重要的意義，CAR細胞療法的潛力也將為改善病人的健康帶來巨大的希望。
近日，一項刊登于雜志eLife上的研究論文中，來自杜克大學的研究人員*在實驗室中開發出了可以收縮并外界刺激產應的人工骨骼肌，這種人工骨骼肌或可幫助研究人員進行藥物的測試及研究一些人類機體的肌肉功能。
研究者Nenad Bursac說道，本文研究的亮點在于其可以為臨床試驗提供幫助，后期我們就可以在不危害患者健康的前提下來檢測藥物的效用和安全性;首先研究者以可以生長但不能分化產生肌肉組織的干細胞出發進行研究，隨后研究人員將這種肌源性的前體細胞擴大了1000倍，并將其作為填滿凝膠的3D支架來幫助生成排列整齊的肌肉纖維組織。
為了觀察這些肌肉組織是否可以用作醫學檢測，研究者Bursac教授研究了它們對一系列藥物的反應，包括用于降膽固醇的他汀類藥物和藥物克侖特羅，后者是一種標簽外使用的運動員增強劑藥物。這些藥物的效應可以同患者進行匹配，他汀類藥物具有劑量依賴性效應，其可以引發脂肪積累;而克侖特羅則可以表現出狹窄的效應，增加肌肉收縮，這兩種藥物的作用可以在人類機體中被記錄下來，但克侖特羅在任何劑量下都不會損傷嚙齒類動物的肌肉組織，其可以促進實驗室條件下的人工肌肉組織表現出真正的人類反應。

西班牙

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

CN-CS1 is the first of its kind to enter clinical trials, an autologous CARt cell therapy that recruits NKG2D cell receptors that act as a natural killer cell receptor that targets most tumors Ligands, including hematological and solid tumors, are present in the bloodstream of researchers in their current clinical trials, such as leukemias and myelomas, and the current widespread use of clinical trial therapies has led to their use in cancer research Far-reaching prospects.
As with the next generation of platform technologies, many of the other related therapies are currently undergoing preclinical development. A new generation of platform technology developed by Sentman Laboratories can link CAR T cells with another innovative TCR-inhibitor (TIMs ); TIMs allow CAR therapy to be used in T-cell studies of healthy donors, thereby avoiding Graft-Versus-Host-Disease (GVHD). Once successful, TIM / CAR therapy will minimize the time it takes for therapy and significantly reduce patient expenses.
Last researcher Sentman said we are pleased to have the opportunity to apply the new therapies we developed to clinical treatments that are of great importance for the development of new and promising cancer immunotherapies and the potential of CAR cell therapies to improve patient outcomes Health brings great hope.
Recently, in a research paper published in the international magazine eLife, researchers from Duke University developed, for the first time, artificial skeletal muscles in the laboratory that can shrink and stimulate the production of external stimuli. Such artificial skeletal muscle may help Researchers conduct drug tests and study muscle functions in some human bodies.
Nenad Bursac, a researcher, said the bright spot in this article is that it can help with clinical trials and later on, we can test the efficacy and safety of drugs without compromising the patient's health. First, researchers develop the muscles that can grow but do not differentiate Then, researchers expanded the muscle-derived progenitor cells by a factor of 1000 and used it as a gel-filled 3D scaffold to help create a neatly organized muscle fiber.
To see if these muscle tissues could be used as medical tests, investigator Prof. Bursac studied their response to a range of drugs, including statin and cholesterol clenbuterol, a cholesterol-lowering drug used as an off-label Athlete Enhancer Drugs. The effects of these drugs can be matched to patients, statins have a dose-dependent effect, which can trigger the accumulation of fat; and Clenbuterol can show a narrow effect, increase muscle contraction, the role of these two drugs in Human tissues are recorded, but clenbuterol does not damage rodent muscle tissue at any dose, which can promote artificial human muscle tissue under laboratory conditions to show a real human response.